StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors

Cancer Medicine

Volumn 6, Issue 5, 2017, Pages 883-901

  Sen, Manimala ^a,b   Katragadda, Shanmukh ^a   Ravichandran, Aarthi ^a   Deshpande, Gouri ^a   Parulekar, Minothi ^a   Nayanala, Swetha ^a   Vittal, Vikram ^a   Shen, Weiming ^a   Phooi Nee Yong, Melanie ^a   Jacob, Jemima ^a   Parchuru, Sravanthi ^a,b   Dhanuskodi, Kalpana ^a,b   Eyring, Kenneth ^a   Agrawal, Pooja ^a   Agarwal, Smita ^a   Shanmugam, Ashwini ^a   Gupta, Satish ^a   Vishwanath, Divya ^a,b   Kumari, Kiran ^a,b   Hariharan, Arun K ^a,b   Balaji, Sai A ^a,b   Liang, Qiaoling ^a   Robolledo, Belen ^a   Gauribidanur Raghavendrachar, Vijayashree ^a   Oomer Farooque, Mohammed ^a   Buresh, Cary J ^c   Ramamoorthy, Preveen ^a   Bahadur, Urvashi ^a   Subramanian, Kalyanasundaram ^a   Hariharan, Ramesh ^a   Veeramachaneni, Vamsi ^a   Sankaran, Satish ^a   Gupta, Vaijayanti ^a,b   more..

^a From Strand Life Sciences ^*  (United States)

^b Multispecialty Hospital Shaw Mazumdar Medical Centre   (India)

^c ProPath   (United States)

Author keywords

Clinical utility; immunohistochemistry; next generation sequencing; solid tumors; standard of care therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; COPY NUMBER VARIATION; DECISION MAKING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; LUNG CANCER; MEASUREMENT ACCURACY; MELANOMA; MICROSATELLITE INSTABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; DNA SEQUENCE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE QUALITY; HIGH THROUGHPUT SEQUENCING; METABOLISM; NEOPLASM; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; STANDARD OF CARE; TRANSLOCATION, GENETIC;

EID: 85017148866     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1037     Document Type: Article

References (41)

1. Hoadley, K. A., C. Yau, D. M. Wolf, A. D. Cherniack, D. Tamborero, S. Ng, et al. 2014. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929–944.
2. Kim, K. B., M. E. Cabanillas, A. J. Lazar, M. D. Williams, D. L. Sanders, J. L. Ilagan, et al. 2013. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23:1277–1283.
3. Gunturu, K. S., Y. Woo, N. Beaubier, H. E. Remotti, and M. W. Saif. 2013. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther. Adv. Med. Oncol. 5:143–151.
4. Janjigian, Y. Y. 2016. Lapatinib in gastric cancer: what is the logical next step? J. Clin. Oncol. 34:401–403.
5. Gagan, J., and E. M. Van Allen. 2015. Next-generation sequencing to guide cancer therapy. Genome Med. 7:80.
6. Cottrell, C. E., H. Al-Kateb, A. J. Bredemeyer, E. J. Duncavage, D. H. Spencer, H. J. Abel, et al. 2014. Validation of a next-generation sequencing assay for clinical molecular oncology. J. Mol. Diagn. 16:89–105.
7. Frampton, G. M., A. Fichtenholtz, G. A. Otto, K. Wang, S. R. Downing, J. He, et al. 2013. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31:1023–1031.
8. Singh, R. R., K. P. Patel, M. J. Routbort, N. G. Reddy, B. A. Barkoh, B. Handal, et al. 2013. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J. Mol. Diagn. 15:607–622.
9. Van Allen, E. M., N. Wagle, P. Stojanov, D. L. Perrin, K. Cibulskis, S. Marlow, et al. 2014. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20:682–688.
10. Shan, L., F. Lian, L. Guo, T. Qiu, Y. Ling, J. Ying, et al. 2015. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC. FISH and real-time RT-PCR. PLoS ONE 10:e0120422.
11. Ooi, A., T. Takehana, X. Li, S. Suzuki, K. Kunitomo, H. Iino, et al. 2004. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod. Pathol. 17:895–904.
12. Geiger, T., J. Cox, and M. Mann. 2010. Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet. 6:e1001090.
13. Spencer, D. H., J. K. Sehn, H. J. Abel, M. A. Watson, J. D. Pfeifer, and E. J. Duncavage. 2013. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J. Mol. Diagn. 15:623–633.
14. Alkan, C., J. M. Kidd, T. Marques-Bonet, G. Aksay, F. Antonacci, F. Hormozdiari, et al. 2009. Personalized copy number and segmental duplication maps using next-generation sequencing. Nat. Genet. 41:1061–1067.
15. Gao, N., Y. D. Hu, X. Y. Cao, J. Zhou, and S. L. Cao. 2001. The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 127:359–367.
16. Gazdar, A. F., V. Kurvari, A. Virmani, L. Gollahon, M. Sakaguchi, M. Westerfield, et al. 1998. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78:766–774.
17. Suzuki, M., H. Makinoshima, S. Matsumoto, A. Suzuki, S. Mimaki, K. Matsushima, et al. 2013. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. 104:896–903.
18. Rikova, K., A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, et al. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203.
19. Shi, H., G. Moriceau, X. Kong, M. K. Lee, H. Lee, R. C. Koya, et al. 2012. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3:724.
20. Dearden, S., J. Stevens, Y. L. Wu, and D. Blowers. 2013. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 24:2371–2376.
21. Singhi, A. D., A. Cimino-Mathews, R. B. Jenkins, F. Lan, S. R. Fink, H. Nassar, et al. 2012. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod. Pathol. 25:378–387.
22. Rapp, U. R., C. Korn, F. Ceteci, C. Karreman, K. Luetkenhaus, V. Serafin, et al. 2009. MYC is a metastasis gene for non-small-cell lung cancer. PLoS ONE 4:e6029.
23. Staff, S., J. Isola, M. Jumppanen, and M. Tanner. 2010. Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol. Rep. 23:307–312.
24. Pino, M. S., and D. C. Chung. 2010. The chromosomal instability pathway in colon cancer. Gastroenterology 138:2059–2072.
25. Dar, A. A., L. W. Goff, S. Majid, J. Berlin, and W. El-Rifai. 2010. Aurora kinase inhibitors–rising stars in cancer therapeutics? Mol. Cancer Ther. 9:268–278.
26. Hilton, J. F., and G. I. Shapiro. 2014. Aurora kinase inhibition as an anticancer strategy. J. Clin. Oncol. 32:57–59.
27. Chang, J., X. Liu, S. Wang, Z. Zhang, Z. Wu, X. Zhang, et al. 2014. Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. PLoS ONE 9:e105524.
28. Kim, J. C., S. A. Roh, D. H. Cho, T. W. Kim, S. N. Yoon, C. W. Kim, et al. 2009. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anticancer Res. 29:3115–3123.
29. Chen, S. P., C. C. Wu, S. Z. Lin, J. C. Kang, C. C. Su, Y. L. Chen, et al. 2009. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. Am. J. Clin. Oncol. 32:122–126.
30. Martino-Echarri, E., B. R. Henderson, and M. G. Brocardo. 2014. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget 5:9889–9900.
31. Buffery, D. 2015. The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer. Am. Health Drug Benefits 8:216–222.
32. Boland, C. R., and A. Goel. 2010. Microsatellite instability in colorectal cancer. Gastroenterology 138:2073––87 e3.
33. Antonelli, A., P. Fallahi, S. M. Ferrari, C. Mancusi, M. Colaci, L. Santarpia, et al. 2012. RET TKI: potential role in thyroid cancers. Curr. Oncol. Rep. 14:97–104.
34. Kadota, M., M. Sato, B. Duncan, A. Ooshima, H. H. Yang, N. Diaz-Meyer, et al. 2009. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 69:7357–7365.
35. Etnyre, D., A. L. Stone, J. T. Fong, R. J. Jacobs, S. B. Uppada, G. M. Botting, et al. 2014. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol. Ther. 15:1129–1141.
36. Kawakami, H., I. Okamoto, W. Okamoto, J. Tanizaki, K. Nakagawa, and K. Nishio. 2014. Targeting MET amplification as a new oncogenic driver. Cancers (Basel) 6:1540–1552.
37. Turner, N., A. Pearson, R. Sharpe, M. Lambros, F. Geyer, M. A. Lopez-Garcia, et al. 2010. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094.
38. Toy, W., Y. Shen, H. Won, B. Green, R. A. Sakr, M. Will, et al. 2013. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45:1439–1445.
39. Li, S., D. Shen, J. Shao, R. Crowder, W. Liu, A. Prat, et al. 2013. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4:1116–1130.
40. Ingle, J. N., V. J. Suman, K. M. Rowland, D. Mirchandani, A. M. Bernath, J. K. Camoriano, et al. 2006. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. 24:1052–1056.
41. Herzog, T. J., D. Spetzler, N. Xiao, K. Burnett, T. Maney, A. Voss, et al. 2016. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget 7:19840–19849.